YPYanan Pang

Yanan Pang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yanan Pang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Rui Wang

    Center for Medical Research and Innovation, Shanghai Pudong Hospital, Human Phenome Institute, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Fudan University, Shanghai, 200438, China; International Human Phenome Institutes, Shanghai, 200438, China

    3 shared publications
  • Yongfang Li

    School of Food Science and Engineering, Foshan University, Foshan 528231, China

    3 shared publications
  • Bo Tian

    Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, China

    2 shared publications
  • De-Jian Bian

    Department of Emergency, Changhai Hospital, Naval Medical University, Shanghai, China

    2 shared publications
  • Feng Qian

    Fudan University

    2 shared publications
  • Kaiming Guo

    State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Human Phenome Institute, Pudong Hospital, Fudan University, Shanghai 200438, China

    2 shared publications

Latest Publications

  • Open Access

    PSMD4 promotes malignant phenotypes and is associated with angiogenesis-related signaling and immune remodeling in hepatocellular carcinoma

    by Qiuyi Wang, Hanxuan Yang, Yanan Pang, Chanyan Zhu

    Proteasome 26 S non-ATPase subunit 4 (PSMD4) is implicated in various cancers, but its role in hepatocellular carcinoma (HCC) is unclear. This study investigates PSMD4 expression, prognostic value, and functions in HCC progression, angiogenesis, and immune regulation. TCGA-LIHC was used as the training cohort and ICGC-LIRI as an external validation cohort to assess PSMD4 expression and prognostic value. Human Protein Atlas (HPA) immunohistochemistry data were used to evaluate PSMD4 protein expression. Survival, ROC, nomogram, functional enrichment, immune infiltration, single-cell, and cell-cell communication analyses were performed. Single-cell RNA-seq data from GSE146409 were used to assess cell-type-specific PSMD4 expression and intercellular communication patterns. Spatial transcriptomics data from HRA000437 were used to visualize the spatial distribution of PSMD4 expression in HCC tissues. The biological role of PSMD4 was validated in Huh7 and HepG2 cells using qRT-PCR, CCK-8, colony formation, wound-healing, and western blot assays. PSMD4 was significantly upregulated in HCC in both TCGA-LIHC and ICGC-LIRI cohorts, with positive protein expression confirmed by HPA immunohistochemistry. High PSMD4 expression was associated with poorer overall survival and showed moderate predictive performance for survival outcomes. Enrichment analyses linked PSMD4 to cell-cycle progression, DNA replication, genomic instability, and angiogenesis-related pathways. Single-cell analysis indicated that PSMD4 was mainly enriched in malignant hepatocytes and SPP1⁺ tumor-associated fibroblasts, while spatial transcriptomics analysis showed that PSMD4 expression was concentrated in tumor-dense regions. PSMD4 knockdown inhibited HCC cell proliferation, colony formation, and migration, and reduced VEGFA, RAF1, and MEK1/2 expression. Moreover, high PSMD4 expression was associated with decreased antitumor immune infiltration and suppression of immune activation-related genes. PSMD4 is upregulated in HCC and is associated with unfavorable prognosis. Functional assays suggest that PSMD4 contributes to malignant phenotypes and angiogenesis-related signaling in HCC cells, while computational immune analyses indicate an association between high PSMD4 expression and an immunosuppressive immune landscape. These findings suggest that PSMD4 may serve as a potential prognostic biomarker and candidate therapeutic target in HCC.

  • STAR-CRISPR: a one-pot ultraspecific CRISPR strategy for rapid, visualized SNV detection and genotyping in point-of-care diagnostics

    by Dianwei Liu, Guoxiu Ma, Linlin Bai, Kaiming Guo, Ting Wang, Zhaoyang Jiang, Feng Qian, Yuanchen Wang, Yanan Pang, Wenbin Zou, et al.


  • Open Access

    utPCR: A Strategy for the Highly Specific and Absolutely Quantitative Detection of Single Molecules within Only Minutes

    by Rui Wang, Ying Liu, Shuaiwei Chen, Linlin Bai, Kaiming Guo, Yanan Pang, Feng Qian, Yongfang Li, Li Ding, Yongming Wang

    Bloodstream infection is a major health problem worldwide, with extremely high mortality. Detecting infection in the early stage is challenging due to the extremely low concentration of bacteria in the blood. Digital PCR provides unparalleled sensitivity and can achieve absolute quantification, but it is time-consuming. Moreover, the presence of unavoidable background signals in negative controls poses a significant challenge for single-molecule detection. Here, we propose a novel strategy called “Ultrafast flexible thin tube-based droplet digital PCR (utPCR)” that can shorten the digital PCR process from 2 h to only 5 min, with primer annealing/extension time reduced from minutes to only 5 s. Importantly, the ultrafast PCR eliminates nonspecific amplification and thus enables single-molecule detection. The utPCR enabled the sensitive detection and digital quantification of E. coli O157 in the high background of a 106-fold excess of E. coli K12 cells. Moreover, this method also displayed the potential to detect rare pathogens in blood samples, and the limit of detection (LOD) could be as low as 10 CFU per mL of blood without false positive results. Considered ultrafast (<5 min) and highly sensitive (single-molecule detection), the utPCR holds excellent prospects in the next generation of molecular diagnosis.


  • Open Access

    utPCR: A Strategy for Highly Specific and Absolutely Quantitative Detection of Single Molecules within Only Minutes

    by Rui Wang, Ying Liu, Shuaiwei Chen, Linlin Bai, Kaiming Guo, Yanan Pang, Feng Qian, Yongfang Li, Li Ding, Yongming Wang

    Bloodstream infection is a major health problem worldwide, with extremely high mortality. Detecting infection in the early stage is challenging due to the extremely low concentration of bacteria in the blood. Digital PCR provides unparalleled sensitivity and can achieve absolute quantification, but it is time-consuming. Moreover, the presence of unavoidable background signals in negative controls poses a significant challenge for single-molecule detection. Here, we propose a novel strategy called “Ultrafast flexible thin tube-based droplet digital PCR (utPCR)” that can shorten the digital PCR process from 2 hours to only 5 minutes, with primer annealing/extension time reduced from minutes to only 5 seconds. Importantly, the ultrafast PCR eliminates the nonspecific amplification and thus enables single-molecular detection. The utPCR enabled sensitive detection and digital quantification of E. coli O157 in the high background of 106-fold excess of E. coli K12 cells. Moreover, this method also displayed the potential to detect rare pathogens in blood samples, and the limit of detection (LOD) could be as low as 10 CFU per mL of blood without false positive results. Considering ultrafast (<5 min) and highly sensitive (single-molecule detection), the utPCR holds excellent prospects in the next generation of molecular diagnosis.

  • Open Access

    Knowledge mapping of alternative splicing of cancer from 2012 to 2021: A bibliometric analysis

    by Bo Tian, Yan Bian, De-Jian Bian, Ye Gao, Xun Zhang, Si-Wei Zhou, Yan-Hui Zhang, Ya-Nan Pang, Zhao-Shen Li, Luo-Wei Wang

    Background: As a processing method of RNA precursors, alternative splicing (AS) is critical to normal cellular activities. Aberrant AS events are associated with cancer development and can be promising targets to treat cancer. However, no detailed and unbiased study describes the current state of AS of cancer research. We aim to measure and recognize the current state and trends of AS cancer research in this study.Methods: The Web of Science Core Collection was used to acquire the articles. Utilizing three bibliometric tools (CiteSpace, VOSviewer, R-bibliometrix), we were able to measure and recognize the influence and collaboration data of individual articles, journals, and co-citations. Analysis of co-occurrence and burst information helped us identify the trending research areas related to AS of cancer.Results: From 2012 to 2021, the total number of papers on AS of cancer published in 766 academic journals was 3,507, authored by 20,406 researchers in 405 institutions from 80 countries/regions. Research involving AS of cancer genes was primarily conducted in the United States and China; simultaneously, the Chinese Academy of Sciences, Fudan University, and National Cancer Institute were the institutions with strong research capabilities. Scorilas Andreas is the scholar with the most publications, while the most co-citations were generated by Wang, Eric T. Plos One published the most papers on AS of cancer, while J Biol Chem was the most co-cited academic journal in this field. The results of keyword co-occurrence analysis can be divided into three types: molecular (P53, CD44, androgen receptor, srsf3, esrp1), pathological process (apoptosis, EMT, metastasis, angiogenesis, proliferation), and disease (breast cancer, colorectal cancer, prostate cancer, hepatocellular carcinoma, gastric cancer).Conclusion: Research on AS of cancer has been increasing in intensity over the past decade. Current AS of cancer studies focused on the hallmarks of AS in cancer and AS signatures including diagnostic and therapeutic targets. Among them, the current trends are splicing factors regulating epithelial–mesenchymal transition and other hallmarks, aberrant splicing events in tumors, and further mechanisms. These might give researchers interested in this field a forward-looking perspective and inform further research.


  • Open Access

    Knowledge Mapping of Alternative Splicing of Cancer From 2012 to 2021: A Bibliometric Analysis

    by Bo Tian, Yan Bian, De-Jian Bian, Ye Gao, Xun Zhang, Si-Wei Zhou, Yan-Hui Zhang, Ya-Nan Pang, Zhao-Shen Li, Luo-Wei Wang

    Background As a processing method of RNA precursors, alternative splicing plays a critical role in normal cell physiological activities. Aberrant alternative splicing events are associated with cancer development and are promising targets for cancer treatment. However, no detailed and unbiased study describes the current state of alternative splicing of cancer research. This study aims to conduct a bibliometric analysis of alternative splicing of cancer research in the last decade to measure and recognize the current state and trends. Methods Web of Science Core Collection was used to acquire the articles. Utilizing three bibliometric tools (CiteSpace, VOSviewer, R-bibliometrix), we were able to measure and recognize the influence and collaboration data of individual articles, journals, and co-citations. Analysis of co-occurrence and bursts information helped us identify the trending research areas related to alternative splicing of cancer. Results From 2012 to 2021, the total number of papers on alternative splicing of cancer published in 766 academic journals was 3,507, authored by 20,406 researchers in 405 institutions from 80 countries/regions. Research involving alternative splicing of cancer genes was primarily conducted in the United States and China, with the United States retaining the prime status; simultaneously, the Chinese Academy of Sciences, Fudan University and National Cancer Institute were the institutions with strong research capabilities. Scorilas Andreas is the scholar with the most publications, while the most co-citations were generated by Wang, Eric T. Plos One published the most papers on alternative splicing of cancer, while J biol chem was the most co-cited academic journal in this field. Furthermore, these publications covered a wide range of areas, but were still primarily focused on the fields of molecular, biology, and immunology. The results of keyword co-occurrence analysis can be divided into three types: molecular (P53, CD44, Androgen receptor, SRSF3, ESRP1), pathological process (apoptosis, EMT, metastasis, angiogenesis, proliferation), and disease (breast cancer, colorectal cancer, prostate cancer, hepatocellular carcinoma, gastric cancer). Conclusion Research on alternative splicing of cancer has been a hot topic over the past decade, increasing in intensity each year. Current alternative splicing of cancer studies focused on hallmarks of alternative splicing in cancer, and alternative splicing signatures including diagnostic and therapeutic targets. Among them, the current trends are splicing factors regulating epithelial-mesenchymal transition and other hallmarks, aberrant splicing events in tumors, and further mechanisms. These might give researchers interested in this field a forward-looking perspective and inform further research.

  • VIR-CRISPR: Visual in-one-tube ultrafast RT-PCR and CRISPR method for instant SARS-CoV-2 detection

    by Rui Wang, Yongfang Li, Yanan Pang, Fang Zhang, Fuyou Li, Shihua Luo, Chunyan Qian